Table 2: Characteristics of the studies included in the review: EGFR mutation testing as a predictor of response to gefitinib compared with chemotherapy in the first-line setting.

Author, year	Patient selection	Design	Tissue available/ pts treated	Mutated/ assessable pts (%)	Median PFS, ORR, OS [p-value]
Subset analyses of the phase III trials for selected patients based on clinical characteristics
					EGFR Mutated		EGFR Wild-type
					G	C+P	G	C+P
Mok, 2009 IPASS (n=1217)	Asian 99.7% Female 79% Non- or former light smokers 99.8% Adenocarcinoma 96.3%	Gefitinib vs. carboplatin/ paclitaxel Phase III RCT	683/1217 (56%)	261/437 (60%)	PFS HR, 0.48 (0.36-0.64) ORR 71.2 vs. 47.3 OS HR, 0.78 (0.50-1.20)		PFS HR, 2.85 (2.05-3.98) ORR 1.1 vs. 23.5 OS HR, 1.39 (0.92-2.09)
					G	Cis+G	G	Cis+G
Lee, 2009 FIRST-SIGNAL (n=309)	Asian Female Never-smokers Adenocarcinoma	Gefitinib vs. cisplatin- gemcitabine Phase III RCT	92/309 (30%)	42/96 (44%)	PFS 8.5 vs. 6.7 months HR, 0.61 (95%CI, 0.31-1.22) ORR 84.6 vs. 37.5 [0.002] OS 30.6 vs. 26.5 months HR, 0.82 (95%CI, 0.35-1.92)		NR
Subset analyses of phase III trials pf patients selected according to EGFR mutation status
					G	C+P	G	C+P
Maemondo, 2010 NEJ002 (n=230)	Asian 100% Female 64% Never-smokers 62% Adenocarcinoma 93%	Gefitinib vs. Carboplatin/ paclitaxel Phase III RCT			PFS 10.8 vs. 5.4 months HR, 0.30 (95%CI, 0.22-0.41) ORR 73.7% vs. 30.7% OS 30.5 vs. 23.6 months [NS]		0
					G	Cis+D	G	Cis+D
Mitsudomi, 2010 WJTOG3405 (n=177)	Asian 100% Female 69% Never-smokers 69% Adenocarcinoma 98%	Gefitinib vs. cisplatin- docetaxel Asian, female, adendocarcinoma Never-smoker			PFS 9.2 vs. 6.3 months HR, 0.48 (95%CI, 0.33-0.71) ORR 62.1% vs. 32.2% [P<0.0001]		0

Abbreviations: PFS, Progression-free survival; ORR, Objective response rate; OS, overall survival; HR, Hazard ratio; G, gefitinib; C, Cisplatin; P, paclitaxel; Cis, Cisplatin; D, docetaxel; NR, Not reported.